54. 成人発症スチル病 Disease details / Clinical trials / Drug dev / DR info

5-ALA
   Kawakami Atsushi
      2020   -   JPRN-jRCTs071190042   -
Aminolevulinic acid
   Kawakami Atsushi
      2023   Phase 2   JPRN-jRCT2071220086   -
      2022   Phase 2   JPRN-jRCT2071220040   -
Anakinra
   Helsinki University
      2005   Phase 2   NCT01033656   Sweden
   Landstinget i Uppsala län
      2006   -   EUCTR2005-003173-24-SE   Finland;Sweden
   Sydvestjysk Sygehus
      2006   Phase 2   EUCTR2005-003173-24-DK   Denmark;Finland;Sweden
   Takeshi KUROSAWA
      2023   Phase 3   JPRN-jRCT2031220222   -
Arava
   Landstinget i Uppsala län
      2006   -   EUCTR2005-003173-24-SE   Finland;Sweden
Azathioprin
   Landstinget i Uppsala län
      2006   -   EUCTR2005-003173-24-SE   Finland;Sweden
   Sydvestjysk Sygehus
      2006   Phase 2   EUCTR2005-003173-24-DK   Denmark;Finland;Sweden
Baricitinib
   Tianjin Medical University General Hospital
      2020   -   ChiCTR2200061599   China
Camoteskimab
   Apollo Therapeutics Ltd
      2021   Phase 1   NCT04752371   Belgium;Poland;Ukraine;United States
Canakinumab
   Charite University, Berlin, Germany
      2012   Phase 2   NCT02204293   Germany
   Charité - Universitätsmedizin Berlin
      2012   Phase 2   EUCTR2011-001027-20-DE   Germany
   Novartis Pharmaceuticals
      2021   Phase 3   NCT04717635   Japan
   Yamada Hiroyuki
      2021   Phase 3   JPRN-jRCT2011200022   -
Comparators
   Helsinki University
      2005   Phase 2   NCT01033656   Sweden
Cyclosporin
   Department of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
      2021   Phase 0   ChiCTR2000036690   China
Cyclosporin A
   Department of Rheumatology, Renji Hospital South Campus, School of Medicine, Shanghai JiaoTong University
      2017   -   ChiCTR-INR-17013144   China
   Sydvestjysk Sygehus
      2006   Phase 2   EUCTR2005-003173-24-DK   Denmark;Finland;Sweden
Cyklosporin A
   Landstinget i Uppsala län
      2006   -   EUCTR2005-003173-24-SE   Finland;Sweden
Deferasirox
   South Hospital of Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine
      2020   Phase 0   ChiCTR2000034186   China
Emapalumab
   Ochiai Kazuya
      2023   Phase 2-3   JPRN-jRCT2031220187   Belgium;Canada;China;Czechia;France;Germany;Italy;Japan;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
   Swedish Orphan Biovitrum
      2018   Phase 2   NCT03311854   France;Italy;Netherlands;Spain;United Kingdom;United States
   Swedish Orphan Biovitrum AG
      2017   Phase 2   EUCTR2016-004223-23-GB   Canada;France;Italy;Netherlands;Spain;United Kingdom;United States
Etoposide
   Department of Rheumatology, Renji Hospital South Campus, School of Medicine, Shanghai JiaoTong University
      2017   -   ChiCTR-INR-17013144   China
EU/1/09/564/004
   Charité - Universitätsmedizin Berlin
      2012   Phase 2   EUCTR2011-001027-20-DE   Germany
GNR-086
   AO GENERIUM
      2023   Phase 3   NCT06497491   Russian Federation
Ilaris
   AO GENERIUM
      2023   Phase 3   NCT06497491   Russian Federation
   Charité - Universitätsmedizin Berlin
      2012   Phase 2   EUCTR2011-001027-20-DE   Germany
Imurel
   Landstinget i Uppsala län
      2006   -   EUCTR2005-003173-24-SE   Finland;Sweden
Kineret 100 MG injection
   Landstinget i Uppsala län
      2006   -   EUCTR2005-003173-24-SE   Finland;Sweden
Kineret injection
   Landstinget i Uppsala län
      2006   -   EUCTR2005-003173-24-SE   Finland;Sweden
   Sydvestjysk Sygehus
      2006   Phase 2   EUCTR2005-003173-24-DK   Denmark;Finland;Sweden
Leflunomide
   Landstinget i Uppsala län
      2006   -   EUCTR2005-003173-24-SE   Finland;Sweden
   Sydvestjysk Sygehus
      2006   Phase 2   EUCTR2005-003173-24-DK   Denmark;Finland;Sweden
Methotrexate
   Landstinget i Uppsala län
      2006   -   EUCTR2005-003173-24-SE   Finland;Sweden
   Sydvestjysk Sygehus
      2006   Phase 2   EUCTR2005-003173-24-DK   Denmark;Finland;Sweden
MTX
   Department of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
      2021   Phase 0   ChiCTR2000036690   China
NI-0501
   Swedish Orphan Biovitrum AG
      2017   Phase 2   EUCTR2016-004223-23-GB   Canada;France;Italy;Netherlands;Spain;United Kingdom;United States
Prednisolone
   Kawakami Atsushi
      2020   -   JPRN-jRCTs071190042   -
RPH-104
   R-Pharm International, LLC
      2023   Phase 3   NCT05432960   Russian Federation
Salazopyrin EN
   Landstinget i Uppsala län
      2006   -   EUCTR2005-003173-24-SE   Finland;Sweden
Sandimmun neoral
   Landstinget i Uppsala län
      2006   -   EUCTR2005-003173-24-SE   Finland;Sweden
Sulfasalazin
   Landstinget i Uppsala län
      2006   -   EUCTR2005-003173-24-SE   Finland;Sweden
   Sydvestjysk Sygehus
      2006   Phase 2   EUCTR2005-003173-24-DK   Denmark;Finland;Sweden
Tadekinig alfa
   AB2 Bio Ltd.
      2015   Phase 2   NCT02398435   France;Germany;Switzerland
Tocilizumab
   Department of Rheumatology & Clinical Immunology,Saitama Medical Center, Saitama Medical Universitity
      2012   -   JPRN-UMIN000007019   Japan
   Division of Rheumatology & Clinical Immunology, Jichi Medical University
      2008   -   JPRN-UMIN000001457   Japan
      2008   -   JPRN-UMIN000001250   Japan